{"nctId":"NCT01272219","briefTitle":"Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALEâ„¢ - Obesity and Pre-diabetes","startDateStruct":{"date":"2011-06-01","type":"ACTUAL"},"conditions":["Metabolism and Nutrition Disorder","Obesity"],"count":3731,"armGroups":[{"label":"Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68)","type":"EXPERIMENTAL","interventionNames":["Drug: liraglutide"]},{"label":"Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68)","type":"EXPERIMENTAL","interventionNames":["Drug: placebo"]},{"label":"Liraglutide Placebo, no Pre-diabetes","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]},{"label":"Liraglutide 3.0mg, Pre-diabetes","type":"EXPERIMENTAL","interventionNames":["Drug: liraglutide"]},{"label":"Liraglutide Placebo, Pre-diabetes","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"liraglutide","otherNames":[]},{"name":"placebo","otherNames":[]},{"name":"liraglutide","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Informed consent obtained\n* Body Mass Index (BMI) of 30.0 kg/m\\^2 or above\n* Body Mass Index (BMI) of 27 kg/m\\^2 or above in the presence of co-morbidities of treated or untreated dyslipidemia and/or hypertension\n* Stable body weight\n* Preceding failed dietary effort\n\nExclusion Criteria:\n\n* Known type 1 or type 2 diabetes\n* Glycosylated haemoglobin (HbA1c) of 6.5 % or above (Screening visit 1) or FPG of 126 mg/dL (7 mmol/L) or above (Screening visit 2) or 2 hour post-challenge (OGTT) plasma glucose of 200 mg/dL (11.1 mmol/L) or above (Screening visit 2)\n* Screening calcitonin of 50 ng/L or above\n* Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC)\n* Personal history of non-familial medullary thyroid carcinoma\n* History of acute or chronic pancreatitis\n* Obesity induced by drug treatment\n* Use of approved weight lowering pharmacotherapy\n* Previous surgical treatment of obesity\n* History of major depressive disorder or suicide attempt\n* Uncontrolled hypertension (systolic blood pressure of 160 mmHg or above and/or diastolic blood pressure of 100 mmHg or above)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Fasting Body Weight","description":"The observed mean change from baseline in fasting body weight (%) after 56-weeks of treatment (main treatment period).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.98","spread":"6.67"},{"groupId":"OG001","value":"-2.62","spread":"5.74"}]}]}]},{"type":"PRIMARY","title":"Proportion of Subjects Losing at Least 5% of Baseline Fasting Body Weight.","description":"Percentage of subjects losing at least 5% of baseline fasting body weight after 56-weeks of treatment (main treatment period).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.2","spread":null},{"groupId":"OG001","value":"27.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of Subjects Losing More Than 10% of Baseline Fasting Body Weight","description":"Percentage of subjects losing \\>10% of baseline fasting body weight after 56-weeks of treatment (main treatment period).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.1","spread":null},{"groupId":"OG001","value":"10.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of Subjects With Onset of Type 2 Diabetes","description":"Proportion of subjects with onset of Type 2 diabetes mellitus (T2DM) at week 160 (main + extension treatment period) among subjects with pre-diabetes at baseline - evaluated as time to onset of T2DM. Subjects included in FAS, who were stratified to 160-weeks of treatment (i.e., excluding 37 subjects with pre-diabetes who entered the re-randomised period and including 6 subjects without pre-diabetes incorrectly stratified to the 160-week treatment period).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Waist Circumference (cm)","description":"The observed mean change from baseline in waist circumference (cm) after 56-weeks of treatment (main treatment period).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.19","spread":"7.31"},{"groupId":"OG001","value":"-3.94","spread":"6.58"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Waist Circumference (Subjects With Pre-diabetes at Baseline)","description":"The observed mean change from baseline in waist circumference (subjects with pre-diabetes at baseline) after 160 weeks of treatment (main + extension treatment period). Subjects included in FAS, who were stratified to 160-weeks of treatment (i.e., excluding 37 subjects with pre-diabetes who entered the re-randomised period and including 6 subjects without pre-diabetes incorrectly stratified to the 160-week treatment period).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.87","spread":"8.28"},{"groupId":"OG001","value":"-3.37","spread":"7.47"}]}]}]},{"type":"SECONDARY","title":"Pre-diabetes Status After 56 Weeks of Treatment","description":"Observed percentage of subjects with pre-diabetes status after 56 weeks of treatment (main treatment period).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78.3","spread":null},{"groupId":"OG001","value":"50.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.6","spread":null},{"groupId":"OG001","value":"46.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"1.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"1.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Pre-diabetes Status in Subject With Pre-diabetes at Baseline After 160 Weeks of Treatment","description":"Observed percentage of subjects (subjects with pre-diabetes at baseline) with pre-diabetes status after 160 weeks of treatment (main + extension treatment period). Subjects included in FAS, who were stratified to 160-weeks of treatment (i.e., excluding 37 subjects with pre-diabetes who entered the re-randomised period and including 6 subjects without pre-diabetes incorrectly stratified to the 160-week treatment period).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.9","spread":null},{"groupId":"OG001","value":"36.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.3","spread":null},{"groupId":"OG001","value":"54.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":null},{"groupId":"OG001","value":"6.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Fasting Body Weight (Subjects With Pre-diabetes at Baseline)","description":"The observed mean change from baseline in fasting body weight (subjects with pre-diabetes at baseline) after 160 weeks of treatment (main + extension treatment period). Subjects included in FAS, who were stratified to 160-weeks of treatment (i.e., excluding 37 subjects with pre-diabetes who entered the re-randomised period and including 6 subjects without pre-diabetes incorrectly stratified to the 160-week treatment period).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.14","spread":"7.34"},{"groupId":"OG001","value":"-1.89","spread":"6.27"}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects Losing at Least 5% and Proportion of Subjects Losing More Than 10% of Baseline Fasting Body Weight (Subjects With Pre-diabetes at Baseline)","description":"Percentage of subjects losing \\>=5% and percentage of subjects losing \\>10% of baseline fasting body weight (pre-diabetic subjects at baseline) after 160-weeks of treatment (main + extension treatment period). Subjects included in FAS, who were stratified to 160-weeks of treatment (i.e., excluding 37 subjects with pre-diabetes who entered the re-randomised period and including 6 subjects without pre-diabetes incorrectly stratified to the 160-week treatment period).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.6","spread":null},{"groupId":"OG001","value":"23.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.8","spread":null},{"groupId":"OG001","value":"9.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Week 56 in Fasting Body Weight (%) (Re-randomised Subjects With No Pre-diabetes)","description":"The observed mean change in fasting body weight (%) from week 56 to week 68 in re-randomised subjects (with no pre-diabetes at baseline) after 12-weeks of treatment (re-randomised treatment period).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.69","spread":"2.58"},{"groupId":"OG001","value":"2.91","spread":"3.01"},{"groupId":"OG002","value":"0.28","spread":"2.39"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Body Weight (%) (Re-randomised Subjects With No Pre-diabetes)","description":"The observed mean change from baseline in fasting body weight (%) in re-randomised subjects (with no pre-diabetes at baseline) after 68 weeks of treatment (main + re-randomised treatment period).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.44","spread":"7.23"},{"groupId":"OG001","value":"-6.77","spread":"7.67"},{"groupId":"OG002","value":"-3.11","spread":"7.52"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":230,"n":1524},"commonTop":["Nausea","Nasopharyngitis","Diarrhoea","Constipation","Headache"]}}}